Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: A novel treatment strategy

Drug and Alcohol Dependence

Volumn 124, Issue 1-2, 2012, Pages 11-18

  Lee, Tong H ^a   Szabo, Steven T ^a   Fowler, J Corey ^a   Mannelli, Paolo ^a   Mangum, O Barry ^b   Beyer, Wayne F ^c   Patkar, Ashwin ^a   Wetsel, William C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Cocaine; Methamphetamine; Pharmacological treatment; Substance abuse; Synaptic plasticity

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; KETANSERIN; METHAMPHETAMINE; METHYLPHENIDATE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PERGOLIDE; PSYCHOSTIMULANT AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 3 ANTAGONIST;

BEHAVIOR SENSITIZATION; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; HUMAN; MEMORY CONSOLIDATION; METHAMPHETAMINE DEPENDENCE; MONOTHERAPY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SENSITIZATION; VALVULAR HEART DISEASE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM SENSITIZATION; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; ONDANSETRON; RATS; SELF ADMINISTRATION; SEROTONIN ANTAGONISTS; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 84862802570     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.01.021     Document Type: Review

References (105)

1. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
2. Angrist B.M., Gershon S. The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. Biol. Psychiatry 1970, 2:95-107.
3. Bernardi R.E., Lattal K.M., Berger S.P. Anisomycin disrupts a contextual memory following reactivation in a cocaine-induced locomotor activity paradigm. Behav. Neurosci. 2007, 121:156-163. 2007.
4. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4:517-529.
5. Bhatia K.S., Szabo S.T., Fowler J.C., Wetsel W.C., Lee T.H. Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. Behav. Brain Res. 2011, 223:227-232.
6. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol. Biochem. Behav. 1990, 35:955-962.
7. Barros H.M., Miczek K.A. Withdrawal from oral cocaine in rate: ultrasonic vocalizations and tactile startle. Psychopharmacology (Berl.) 1996, 125:379-384.
8. Centonze D., Siracusano A., Calabresi P., Bernardi G. Removing pathogenic memories: a neurobiology of psychotherapy. Mol. Neurobiol. 2005, 32:123-132.
9. Chen Q., Lee T.H., Wetsel W.C., Sun Q.A., Liu Y., Davidson C., Xiong X., Ellinwood E.H., Zhang X. Reversal of cocaine sensitization-induced behavioral sensitization normalizes GAD67 and GABAA receptor alpha2 subunit expression, and PKC zeta activity. Biochem. Biophys. Res. Commun. 2007, 356:733-738.
10. Chen Q., Xiong X., Lee T.H., Liu Y., Wetsel W.C., Zhang X. Neural plasticity and addiction: integrin-linked kinase and cocaine behavioral sensitization. J. Neurochem. 2008, 107:679-689.
11. 845 phosphorylation. J. Mol. Neurosci. 2010, 40:284-294.
12. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry 1999, 156:11-18.
13. Cho A.K., Melega W.P., Kuczensk R., Segal D.S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001, 39:161-166.
14. Colfax G., Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr. HIV/AIDS Rep. 2005, 2:194-199.
15. Connell P.H. Amphetamine Psychosis (Maudsley Monographs No. 5) 1958, Chapman & Hall, London.
16. Contoreggi C., Herning R.I., Koeppl B., Simpson P.M., Negro P.J., Fortner-Burton C., Hess J. Treatment-seeking inpatient cocaine abusers show hypothalamic dysregulation of both basal prolactin and cortisol secretion. Neuroendocrinology 2003, 78:154-162.
17. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol. Biochem. Behav. 1990, 36:97-104.
18. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1087-1099.
19. Darke S., Kaye S., McKetin R., Duflou J. Physical and Psychological Harms of Psychostimulant Use: NDARC Technical Report No. 286 2007, National Drug and Alcohol Research Centre, Sydney.
20. Davidson C., Gopalan R., Ahn C., Chen Q., Mannelli P., Patkar A.A., Weese G.D., Lee T.H., Ellinwood E.H. Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. Eur. J. Pharmacol. 2007, 565:113-118.
21. Davidson C., Lazarus C., Lee T.H., Ellinwood E.H. Behavioral sensitization is greater after repeated versus single chronic cocaine dosing regimens. Eur. J. Pharmacol. 2002, 441:75-78.
22. Davidson C., Lazarus C., Xiong X., Lee T.H., Ellinwood E.H. 5-HT2 antagonists given in the acute withdrawal from daily cocaine injections reverse established sensitization. Eur. J. Pharmacol. 2002, 453:255-263.
23. Davidson C., Lee T.H., Ellinwood E.H. The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine. Eur. J. Pharmacol. 2004, 499:355-356.
24. Davidson C., Lee T.H., Xiong Z., Ellinwood E.H. Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 2002, 27:542-553.
25. de Leeuw A.S., Westenberg H.G. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J. Psychiatr. Res. 2008, 42:894-901.
26. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148:224-230.
27. Donovan E. Propranolol use in the prevention and treatment of posttraumatic stress disorder in military veterans: forgetting therapy revisited. Perspect. Biol. Med. 2010, 53:61-74.
28. Drake R.E., Wallach M.A. Substance abuse among the chronic mentally ill. Hosp. Community Psychiatry 1989, 45:1041-1045.
29. D'Souza M.S., Markou A. Neural substrates of psychostimulant withdrawal-induced anhedonia. Curr. Top. Behav. Neurosci. 2010, 119-178.
30. Elkashef A., Vocci F., Hanson G., White J., Wickes W., Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst. Abuse 2008, 29:31-49.
31. Ellinwood E.H. Amphetamine psychosis: II. Theoretical implications. Int. J. Neuropsychiatry 1968, 4:45-54.
32. Ellinwood E.H., Lee T.H. Dose- and time-dependent effects of stimulants. Pharmacology and Toxicology of Amphetamine and Related Designer Drugs 1989, vol. 94:323-340. NIDA Monograph.
33. Ellinwood E.H., Davidson C., Yu G.-Z., King G.R., Lee T.H. Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens. Eur. Neuropsychopharmacol. 2002, 12:407-415.
34. European Monitoring Centre for Drugs and Drug Addiction, 2010. Amphetamines, ecstasy and hallucinogenic substances. Annual report 2010: The State of the Drugs Problem in Europe. Luxembourg.
35. Foltin R.W., Fischman M.W. Residual effects of repeated cocaine smoking in humans. Drug Alcohol Depend. 1997, 47:117-124.
36. Fricks-Gleason A.N., Marshall J.F. Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories. Learn Mem. 2008, 26:643-648.
37. Fukushiro D.F., Alvarez Jdo.N., Tatsu J.A., de Castro J.P., Chinen C.C., Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:867-872.
38. Fukushiro D.F., Mari-Kawamoto E., Aramini T.C., Saito L.P., Costa J.M., Josino F.S., Frussa-Filho R. Withdrawal from repeated treatment with amphetamine reduces novelty-seeking behavior and enhances environmental habituation in mice. Pharmacol. Biochem. Behav. 2011, 100:180-184.
39. Fung Y.K., Richard L.A. Behavioural consequences of cocaine withdrawal in rats. J. Pharm. Pharmacol. 1994, 46:150-152.
40. Gawin F.H., Ellinwood E.H. Cocaine and other stimulants. Actions, abuse, and treatment. N. Engl. J. Med. 1988, 318:1173-1182.
41. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in ocaine abusers. Arch. Gen. Psychiatry 1986, 43:107-113.
42. Glasner-Edwards S., Mooney L.J., Marinelli-Casey P., Hillhouse M., Ang A., Rawson R.A. Methamphetamine treatment project corporate authors, psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010, 29:12-20.
43. Gonzales R., Marinelli-Casey P., Shoptaw S., Ang A., Rawson R.A. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J. Subst. Abuse Treat. 2006, 31:195-202.
44. 3 receptors in drug dependence. Drug Alcohol Depend. 1995, 38:155-171.
45. Hall W., Gartner C. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Curr. Opin. Psychiatry 2011, 24:191-196.
46. Haney M., Foltin R.W., Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (Berl.) 1998, 137:15-24.
47. Jaffe J.H., Cascella N.G., Kumor K.M., Sherer M.A. Cocaine-induced cocaine craving. Psychopharmacology (Berl.) 1989, 97:59-64.
48. 3 receptors in inhibitory circuits of the primate cerebral cortex. J. Comp. Neurol. 2000, 417:337-348.
49. Jakab R.L., Goldman-Rakic P.S., Leranth C. Dual role of substance P/GABA axons in cortical neurotransmission: synaptic triads on pyramidal cell spines and basket-like innervation of layer II-III calbindin interneurons in primate prefrontal cortex. Cereb. Cortex 1997, 7:359-373.
50. Janowsky D.S., Davis J.M. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. Adv. Biochem. Psychopharmacol. 1974, 12:317-323.
51. Janowsky D.S., Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 1979, 65:73-77.
52. Jeffcoat A.R., Perez-Reyes M., Hill J.M., Sadler B.M., Cook C.E. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. Drug Metab. Dispos. 1989, 17:153-159.
53. Johnson B.A. Medication treatment of different types of alcoholism. Am. J. Psychiatry 2010, 167:630-639.
54. Johnson B.A., Ait-Daoud N., Elkashef A.M., Smith E.V., Kahn R., Vocci F., Li S.H., Bloch D.A. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int. J. Neuropsychopharmacol. 2008, 11:1-14. Methamphetamine Study Group.
55. Johnson B.A., Roache J.D., Ait-Daoud N., Javors M.A., Harrison J.M., Elkashef A., Mojsiak J., Li S.H., Bloch D.A. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006, 84:256-263.
56. Kampman K.M., Alterman A.I., Volpicelli J.R., Maany I., Muller E.S., Luce D.D., Mulholland E.M., Jawad A.F., Parikh G.A., Mulvaney F.D., Weinrieb R.M., O'Brien C.P. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol. Addict. Behav. 2001, 15:52-59.
57. Kelley J.B., Anderson K.L., Itzhak Y. Long-term memory of cocaine-associated context: disruption and reinstatement. Neuroreport 2007, 18:777-780.
58. Kent J.M. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000, 355:911-918.
59. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am. J. Psychiatry 1985, 142:1259-1264.
60. King G.R., Xiong Z., Douglass S., Ellinwood E.H. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist. Eur. J. Pharmacol. 2000, 394:97-101.
61. King G.R., Xiong Z., Ellinwood E.H. Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine. Psychopharmacology (Berl.) 1998, 135:263-269.
62. Kinsey B.M., Kosten T.R., Orson F.M. Anti-cocaine vaccine development. Expert Rev. Vaccines 2010, 9:1109-1114.
63. Koeltzow T.E., White F.J. Behavioral depression during cocaine withdrawal is associated with decreased spontaneous activity of ventral tegmental area dopamine neurons. Behav. Neurosci. 2003, 117:860-865.
64. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24. 97-29.
65. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
66. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
67. Kuribara H. Can posttreatment with the selective dopamine D2 antagonist, YM-09151-2, inhibit induction of methamphetamine sensitization?. Evaluation by ambulatory activity in mice. Pharmacol. Biochem. Behav. 1994, 49:323-326.
68. Kuribara H. Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol. Psychopharmacology 1995, 119:34-38.
69. Landén M., Thase M.E. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol. Bull. 2006, 39:147-166.
70. LeDuc P.A., Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 1995, 121:407-427.
71. Lee J.L., Di Ciano P., Thomas K.L., Everitt B.J. Disrupting reconsolidation of drug memories reduces cocaine-seeking behavior. Neuron 2005, 47:795-801.
72. Lee J.L., Milton A.L., Everitt B.J. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. J. Neurosci. 2006, 26:5881-5887.
73. Lee T.H., Gao W.Y., Davidson C., Ellinwood E.H. Altered activity of midbrain dopamine neurons following 7-day withdrawal from chronic cocaine abuse is normalized by D2 receptor stimulation during the early withdrawal phase. Neuropsychopharmacology 1999, 21:127-136.
74. Leventhal A.M., Kahler C.W., Ray L.A., Stone K., Young D., Chelminski I., Zimmerman M. Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. Am. J. Addict. 2008, 17:218-223.
75. Levin F.R., McDowell D., Evans S.M., Brooks D., Spano C., Nunes E.V. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am. J. Addict. 1999, 8:120-127.
76. Lewis D.A., González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33:141-165.
77. Li Y., White F.J., Wolf M.E. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology 2000, 151:175-183.
78. Mahoney J.J., Kalechstein A.D., De La Garza R., Newton T.F. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am. J. Addict. 2008, 17:83-98.
79. Malcolm R., Kajdasz D.K., Herron J., Anton R.F., Brady K.T. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000, 60:161-168.
80. Mantsch J.R., Taves S., Khan T., Katz E.S., Sajan T., Tang L.C., Cullinan W.E., Ziegler D.R. Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration. Neurosci. Lett. 2007, 415:269-273.
81. Miller F.T., Tanenbaum J.H. Drug abuse in schizophrenia. Hosp. Community Psychiatry 1989, 40:847-849.
82. Mulvaney F.D., Alterman A.I., Boardman C.R., Kampman K. Cocaine abstinence symptomatology and treatment attrition. J. Subst. Abuse Treat. 1999, 16:129-135.
83. Mutschler N.H., Miczek K.A. Withdrawal from a self administered or non-contingent cocaine binge - differences in ultrasonic distress vocalizations in rats. Psychopharmacology (Berl.) 1998, 136:402-408.
84. Nader K., Hardt O. A single standard for memory: the case for reconsolidation. Nat. Rev. Neurosci. 2009, 10:224-234.
85. Newton T.F., Kalechstein A.D., Duran S., Vansluis N., Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am. J. Addict. 2004, 13:248-255.
86. Newton T.F., Kalechstein A.D., Tervo K.E., Ling W. Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addict. Behav. 2003, 28. 817-321.
87. Pierce R.C., Vanderschuren L.J. Kicking the habit: the neural basis of ingrained behaviors in cocaine addiction. Neurosci. Biobehav. Rev. 2010, 35:212-219.
88. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
89. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
90. Robinson T.E., Berridge K.C. Review. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 363:3137-3146.
91. Sadler R., Herzig V., Schmidt W.J. Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference. Behav. Pharmacol. 2007, 18:699-703.
92. Sarnyai Z., Dhabhar F.S., McEwen B.S., Kreek M.J. Neuroendocrinerelated effects of long-term 'binge' cocaine administration: diminished individual differences in stress-induced corticosterone secretion. Neuroendocrinology 1998, 68:334-344.
93. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 2007, 356:29-38.
94. Schiller D., Monfils M.H., Raio C.M., Johnson D.C., Ledoux J.E., Phelps E.A. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010, 463:36-37.
95. Shalev U., Grimm J.W., Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol. Rev. 2002, 54:1-42.
96. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology 2001, 158:343-539.
97. Sinha R., Garcia M., Paliwal P., Kreek M.J., Rounsaville B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch. Gen. Psychiatry 2006, 63:324-331.
98. Sofuoglu M., Dudish-Poulsen S., Brown S.B., Hatsukami D.K. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend. 2003, 69:273-282.
99. Steketee J.D., Kalivas P.W. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 2011, 63:348-365.
100. Substance Abuse and Mental Health Services Administration, 2008. Office of Applied Studies. Treatment Episode Data Set (TEDS), 1996-2006. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-43, DHHS Publication No. SMA 08-4347. Rockville, MD.
101. Substance Abuse and Mental Health Services Administration, 2010. Office of Applied Studies. Drug abuse warning network, 2007. National estimates of drug-related emergency department visits. Rockville, MD.
102. Substance Abuse and Mental Health Services Administration, 2009. Results from the 2008 national survey on drug use and health. National findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD.
103. Taylor W.A., Gold M.S. Pharmacologic approaches to the treatment of cocaine dependence. West. J. Med. 1990, 152:573-577.
104. Volkow N.D. Substance use disorders in schizophrenia - clinical implications of comorbidity. Schizophr. Bull. 2009, 35:469-472.
105. Zhang X., Lazarus C., Wetsel W.C., Davidson C., Lee T.H., Ellinwood E.H. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology 2007, 32:377-387.